- Home
- EYPT vs PGEN Comparison
EYPT vs PGEN Comparison
Compare EYPT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | PGEN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EYPT | PGEN |
|---|---|---|
| Price | $12.86 | $3.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $31.80 | $7.67 |
| AVG Volume (30 Days) | 1.2M | ★ 3.6M |
| Earning Date | 03-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $230,981,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | $1,031.72 | $478.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.11 |
| 52 Week High | $19.11 | $5.47 |
Technical Indicators
Market Signals| Indicator | EYPT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 36.67 |
| Support Level | $12.05 | $3.22 |
| Resistance Level | $13.32 | $5.10 |
| Average True Range (ATR) | 1.01 | 0.18 |
| MACD | -0.33 | 0.00 |
| Stochastic Oscillator | 3.45 | 26.43 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.